Showing results (1701-1710 of 1,743) with videos related to
Sort By:
Pageof 175
Neurology|October 15, 2017
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional seriesJeffrey M Gelfand, Michael J Bradshaw, Barney J Stern, et al.The Journal of Experimental Medicine|January 8, 2021
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemiaEleni Louka, Benjamin Povinelli, Alba Rodriguez-Meira, et al.Contemporary Clinical Trials|November 20, 2019
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerationsAnne T Reutens, Karin Jandeleit-Dahm, Merlin Thomas, et al.The Lancet. Oncology|November 1, 2019
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trialMark T Drayson, Stella Bowcock, Tim Planche, et al.Internal Medicine Journal|October 21, 2022
Diabetes IN hospital - Glucose and Outcomes in the COVID-19 pandemic (DINGO COVID-19): the 2020 Melbourne hospital experience prior to novel variants and vaccinationsRahul D Barmanray, Joanna Y Gong, Mervyn Kyi, et al.Journal of Medicinal Chemistry|March 7, 2007
Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamidesChuen Chan, Alan D Borthwick, David Brown, et al.The Journal of Clinical Endocrinology and Metabolism|October 29, 2020
Determinants of Cardiovascular Risk in 7000 Youth With Type 1 Diabetes in the Australasian Diabetes Data NetworkJenny J Couper, Timothy W Jones, Melissa Chee, et al.Bioorganic & Medicinal Chemistry Letters|May 16, 2006
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitorsNigel S Watson, David Brown, Matthew Campbell, et al.Bioorganic & Medicinal Chemistry Letters|August 25, 2010
Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SARCharlotte J Mitchell, Stuart P Ballantine, Diane M Coe, et al.The Journal of Clinical Endocrinology and Metabolism|March 6, 2019
SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital AdmissionPeter S Hamblin, Rosemary Wong, Elif I Ekinci, et al.Pageof 175